SWOG clinical trial number
S9623

A Comparison of Intensive Sequential Chemotherapy using Doxorubicin plus Paclitaxel plus Cyclophosphamide with High Dose Chemotherapy and Autologous Hematopoietic Progenitor Cell Support for Primary Breast Cancer in Women with >= 4 Involved Axillary Lymph Nodes, Phase III, Intergroup.

Closed
Phase
Accrual
55%
Published
Abbreviated Title
ADJUVANT: Doxorubicin/paclitaxel/cyclophosphamide vs. High dose chemo and autologous AHPCS
Activated
07/01/1996
Closed
02/15/2001
Participants
NCORP, Members, Medical Oncologists, Radiation Oncologists, Surgeons, Pathologists, ECOG, NCCTG, CALGB

Research committees

Breast Cancer

Treatment

Cisplatin Cyclophosphamide Paclitaxel BCNU Carboplatin Ciprofloxacin hydrochloride Doxorubicin Filgrastim Tamoxifen Thiotepa AC

Eligibility Criteria Expand/Collapse

Hist. doc. breast ca involving >= 4 lymph nodes (at least 10 nodes sampled); no known N3, T4 or M1 dz; mastectomy or breast sparing surgery <= 12 weeks prior to rand.; no prior chemo or hormonal tx; no prior breast RT; no CHF or other significant cardiac dz; no HIV pos.; transplant center participation and approval required; pathology material to be sent for banking; Effective 9/15/00: Southwest Oncology Group institutions must offer ancillary study, S9719.

Publication Information Expand/Collapse

2018

Survival by Hispanic Ethnicity among Cancer Patients Participating in SWOG Clinical Trials

M Chavez-MacGregor;J Unger;A Moseley;S Ramsey;DL Hershman Cancer Apr 15;124(8):1760-1769; Jan 25 [Epub ahead of print]

PMid: PMID29370458 | PMC number: PMC5963502

The association between ASCO Value framework and scientific and clinical impact of SWOG phase III clinical trials

V Nghiem;R Vaidya;M Banegas;D Hershman;J Unger AcademyHealth Annual Research Meeting (June 23-26, 2018, Seattle, WA), poster

2011

High-dose chemotherapy with autologous stem cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials [PMID21768471]

DA Berry;NT Ueno;MM Johnson;X Lei;J Caputo;S Rodenhuis;W Peters;RC Leonard;WE Barlow;M Tallman;J Bergh;NA Nitz;AM Gianni;RL Basser;A Zander;RC Coombes;H Roche;Y Tokuda;E de Vries;G Hortobagyi;JP Crown;P Pedrazzoli;M Bregni;T Demirer Journal of Clinical Oncology 29(24):3214-3223;

2007

Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623 [PMID17404368]

HCF Moore;SJ Green;JR Gralow;SI Bearman;D Lew;WE Barlow;C Hudis;AC Wolff;JN Ingle;HK Chew;AD Elias;RB Livingston;S Martino Journal of Clinical Oncology 25(13):1677-1682

2005

SWOG/Intergroup 9623: a phase III comparison of intensive sequential chemotherapy to high dose chemotherapy and autologous hematopoietic progenitor cell support (ACHPCS) for primary breast cancer in women with >4 involved axillary lymph nodes.

SI Bearman;SJ Green;J Gralow;W Barlow;C Hudis;A Wolff;J Ingle;G Hortobagyi;R Livingston;S Martino Proc of the ASCO, JCO 23(16S):21s (#572)

Other Clinical Trials

SWOG Clinical Trial Number
SWOG-7436

Combined Modality Therapy of Breast Carcinoma Phase III

Research Committee(s)
Breast Cancer
Activated
01/09/1975
Closed
07/18/1979
Accrual
100%
Closed
Phase
III
Published
SWOG Clinical Trial Number
SWOG-7827

Combined Modality Therapy For Breast Carcinoma Phase III

Research Committee(s)
Breast Cancer
Activated
07/16/1979
Closed
08/01/1989
Accrual
100%
Closed
Phase
III
Published